Trial Profile
Abatacept for the Treatment of Refractory Juvenile Dermatomyositis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Aug 2022
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Dermatomyositis
- Focus Adverse reactions; Therapeutic Use
- Acronyms AID
- 15 Mar 2021 Status changed from recruiting to completed.
- 06 Feb 2020 Planned End Date changed from 1 Oct 2019 to 1 Oct 2020.
- 06 Feb 2020 Planned primary completion date changed from 1 Jul 2019 to 1 Jul 2020.